40.59
-0.7099(-1.72%)
Currency In USD
Address
64 Sidney Street
Cambridge, MA 02139
United States of America
Phone
617 588 5555
Website
Sector
Healthcare
Industry
Biotechnology
Employees
357
First IPO Date
February 04, 1997
| Name | Title | Pay | Year Born |
| Mr. Dominick C. Colangelo Esq. | Chief Executive Officer, President & Director | 1.56M | 1964 |
| Ms. Karen Mahoney | Chief Human Resources Officer | 514,445 | 1972 |
| Mr. Sean C. Flynn | Chief Legal Officer | 690,274 | 1974 |
| Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B. | Chief Medical Officer | 705,126 | 1962 |
| Mr. Joseph Anthony Mara Jr. | Chief Financial Officer & Treasurer | 774,166 | 1976 |
| Mr. Michael Halpin | Chief Operating Officer | 819,174 | 1962 |
| Mr. Jonathan D. Siegal | Principal Accounting Officer, Vice President & Corporate Controller | 0 | N/A |
| Mr. Eric Burns | Vice President of Finance & Investor Relations | 0 | N/A |
| Mr. Patrick Helfrich | Vice President of Marketing & Commercial Strategy | 0 | N/A |
| Mr. Patrick J. Fowler | Senior Vice President of Corporate Development & Strategy | 0 | N/A |
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
